Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)

NCT05405166 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT05405166
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05405166 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Active, not recruiting
Start date
June 23, 2022
Completion date
October 22, 2027
Enrollment
531 (actual)
Sites
128

Conditions

As the registry lists them; a condition with its own page is linked.

plasma cell myeloma recurrent